Currently, there are 155.66M common shares owned by the public and among those 140.09M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 18.61% and 0.47% over the past three months. TGTX shares are trading 14.35% year to date (YTD), with the 12-month market performance up to 95.24% higher. It has a 12-month low price of $12.93 and touched a high of $36.84 over the same period. TGTX has an average intraday trading volume of 2.08 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.24%, 11.15%, and 37.53% respectively.
Institutional ownership of TG Therapeutics Inc (NASDAQ: TGTX) shares accounts for 62.89% of the company’s 155.66M shares outstanding.
It has a market capitalization of $5.36B and a beta (3y monthly) value of 2.30. The stock’s trailing 12-month PE ratio is 246.56, while the earnings-per-share (ttm) stands at $0.14. The company has a PEG of 1.56 and a Quick Ratio of 3.91 with the debt-to-equity ratio at 1.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.17% over the week and 5.36% over the month.
Earnings per share for the fiscal year are expected to increase by 569.52%, and 101.97% over the next financial year.
Looking at the support for the TGTX, a number of firms have released research notes about the stock. TD Cowen stated their Buy rating for the stock in a research note on October 29, 2024, with the firm’s price target at $50. Goldman coverage for the TG Therapeutics Inc (TGTX) stock in a research note released on August 02, 2023 offered a Neutral rating with a price target of $12. Jefferies was of a view on June 26, 2023 that the stock is Buy, while BofA Securities gave the stock Underperform rating on May 20, 2022, issuing a price target of $5. B. Riley Securities on their part issued Buy rating on February 23, 2022.
